Guidelines for Reporting Tumor Marker Prognostic Studies
Author Information
Author(s): Lisa M McShane, Douglas G Altman, Willi Sauerbrei, Sheila E Taube, Massimo Gion, Gary M Clark
Primary Institution: US National Cancer Institute
Hypothesis
The guidelines aim to improve the reporting quality of tumor marker studies to enhance their clinical utility.
Conclusion
The guidelines encourage transparent and complete reporting of tumor marker studies to improve their quality and usefulness.
Supporting Evidence
- Many tumor marker studies lack rigorous reporting, leading to inconsistent conclusions.
- Guidelines aim to standardize reporting to improve the quality of tumor marker studies.
- Poor study design and analysis are major barriers to the clinical utility of tumor markers.
Takeaway
This paper provides rules for how scientists should report studies on cancer markers so that others can understand and trust their findings.
Methodology
The guidelines were developed through a collaborative effort among statisticians, clinicians, and laboratory scientists, incorporating feedback from various stakeholders.
Potential Biases
Potential biases include selection bias in patient populations and variability in assay results.
Limitations
The guidelines may not cover all aspects of early marker studies and predictive marker studies require additional considerations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website